ArticleMikrochimica acta2025
A sensitive chemiluminescence aptasensor for adenosine detection based on a nucleic acid cycle amplification strategy.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Three nucleic acid DNA-modified materials were synthesized and used to the highly sensitive and highly selective chemiluminescence (CL) detection of adenosine (ADE) based on a nucleic acid cycle amplification strategy. These materials include magnetic carbon nanotubes modified with an adenosine aptamer and its complementary DNA (MCNTs@Apt-cDNA), octahedral Fe3O4 nanoparticles modified with hairpin DNA (Octa-Fe3O4@H1DNA), and carbon quantum dot@luminol composites modified with auxiliary DNA (CQDs@luminol-sDNA). They were used to construct a CL aptasensor for ADE detection. When ADE is present, ADE molecules specifically recognize and bind to the Apt in MCNTs@Apt-cDNA, leading to the release of cDNA. The released cDNA then reacts with H1DNA in Octa-Fe3O4@H1DNA, opening the hairpin structure of H1DNA. Subsequently, Octa-Fe3O4 interacts with CQDs@luminol-sDNA to release cDNA again. This released cDNA triggers the opening of H1DNA in Octa-Fe3O4@H1DNA once more, thereby realizing the repeated recycling of cDNA and generating Octa-Fe3O4@H1DNA conjugated with a large amount of CQDs@luminol-sDNA. For the resulting Octa-Fe3O4@H1DNA(CQDs@luminol-sDNA)n complex, luminol acts as the CL substance, while Octa-Fe3O4 and CQDs serve as catalysts. The short distance between luminol and catalysts enhances the CL intensity. As the concentration of ADE molecules increases, more CQDs@luminol-sDNA binds to Octa-Fe3O4@H1DNA, resulting in increased CL intensity and enabling the quantitative detection of ADE. The aptasensor exhibited a linear range of 1.0 × 10− 4 ~ 10.0 nmol/L and a detection limit of 3.2 × 10− 5 nmol/L for ADE detection. Finally, it was successfully applied to the detection of ADE in serum samples.
Indexed as
Identifiers
41419679What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.